Your browser doesn't support javascript.
loading
Antiphospholipid antibodies can specifically target placental mitochondria and induce ROS production.
Zussman, Rachel; Xu, Lance Y; Damani, Tanvi; Groom, Katie M; Chen, Qi; Seers, Blake; Viall, Chez A; Chamley, Lawrence W; Hickey, Anthony.
Afiliación
  • Zussman R; Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand; School of Biological Sciences, University of Auckland, Auckland, New Zealand. Electronic address: r.zussman@auckland.ac.nz.
  • Xu LY; Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.
  • Damani T; School of Biological Sciences, University of Auckland, Auckland, New Zealand.
  • Groom KM; Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Chen Q; Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.
  • Seers B; Department of Statistics, University of Auckland, Auckland, New Zealand.
  • Viall CA; Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.
  • Chamley LW; Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.
  • Hickey A; School of Biological Sciences, University of Auckland, Auckland, New Zealand.
J Autoimmun ; 111: 102437, 2020 07.
Article en En | MEDLINE | ID: mdl-32224053
Women with antiphospholipid antibodies (aPL) have increased risks of pregnancy complications, including a ten-fold increased risk of preeclampsia, which is potentially triggered by the release of placental toxins. Previously, aPL were shown to enter the outer layer of the placenta, the syncytiotrophoblast, associate with mitochondria, and alter mitochondrial function. We hypothesised that aPL may also increase mitochondrial reactive oxygen species (ROS) production, leading to cellular dysfunction and release of toxins. First trimester placental explants were incubated with monoclonal aPL, ID2 and IIC5 (25, 50, and 100 µg/mL), for 3 h at 37 °C and ROS production followed using CellROX Deep Red. In addition, the candidate treatment compounds chloroquine, melatonin, and Mito-Q were tested at therapeutic concentrations for their ability to prevent ROS production. Mitochondria isolated from term placentae were incubated with fluorescently-labelled ID2, IIC5, or control IgG antibodies (2.5, 5, 10, or 20 µg/mL) for 30 min, and mitochondria with bound antibodies were quantified using flow cytometry. In addition, respirometry coupled with fluorimetry was used to interrogate explant mitochondrial respiration and ROS production following incubation with 25, 50, or 100 µg/mL ID2, IIC5, or control IgG for 3 h at 37 °C. ID2 increased explant ROS production in a manner that was completely prevented by the endocytosis inhibitor chloroquine, and partially prevented by the antioxidants melatonin and Mito-Q. Both ID2 and IIC5 displayed a greater ability to bind isolated mitochondria than control antibodies, and increased ROS production attributable to the mitochondrial enzyme glycerol 3-phosphate dehydrogenase (mGPDH). Our evidence supports the hypothesis that aPL interact with syncytiotrophoblast mitochondria, likely via the binding of cardiolipin and ß2 glycoprotein I in mitochondrial membranes, and induce ROS production which contributes to overall oxidative stress and placental dysfunction.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Placenta / Trofoblastos / Especies Reactivas de Oxígeno / Mitocondrias Límite: Female / Humans / Pregnancy Idioma: En Revista: J Autoimmun Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Placenta / Trofoblastos / Especies Reactivas de Oxígeno / Mitocondrias Límite: Female / Humans / Pregnancy Idioma: En Revista: J Autoimmun Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article